Share Name Share Symbol Market Type Share ISIN Share Description
Destiny Pharma Plc LSE:DEST London Ordinary Share GB00BDHSP575 ORD GBP0.01
  Price Change % Change Share Price Shares Traded Last Trade
  1.00 2.6% 39.50 12,619 08:11:07
Bid Price Offer Price High Price Low Price Open Price
38.00 41.00 39.50 38.50 38.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -6.27 -8.90 29
Last Trade Time Trade Type Trade Size Trade Price Currency
12:19:52 O 90 38.00 GBX

Destiny Pharma (DEST) Latest News (4)

More Destiny Pharma News
Destiny Pharma Investors    Destiny Pharma Takeover Rumours

Destiny Pharma (DEST) Discussions and Chat

Destiny Pharma Forums and Chat

Date Time Title Posts
05/7/202217:47Destiny Pharma plc787

Add a New Thread

Destiny Pharma (DEST) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Destiny Pharma trades in real-time

Destiny Pharma (DEST) Top Chat Posts

Destiny Pharma Daily Update: Destiny Pharma Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker DEST. The last closing price for Destiny Pharma was 38.50p.
Destiny Pharma Plc has a 4 week average price of 38.50p and a 12 week average price of 38.50p.
The 1 year high share price is 140p while the 1 year low share price is currently 38.50p.
There are currently 73,307,105 shares in issue and the average daily traded volume is 15,781 shares. The market capitalisation of Destiny Pharma Plc is £28,956,306.48.
sicilian_kan: The share price here is ridiculously undervalued. £31m for 2x Phase 3 ready assets with excellent data behind them! And they raised £6.5m cash less than 2 months ago so have zero need for funding!
sev22: I fully concur with a poster this morning on the LSE Bulletin Board for DEST titled: 'Hidden Gem' I have to admit, DEST has been a poor performer in recent months even though the company has indeed made very good progress in it’s lead assets M3 and XF-93. I think it’s an absolute bargain at this level and am expecting a quick move up to 125p and beyond once the placing shares are absorbed by the market and key newsflow begins. SUMMARY: £36m market cap XF-93 asset due FDA Ph3 design approval Q2 M3 asset in advanced partnering discussions for Ph3 SPOR-COV progressing well (not core but a good bonus) Recent placing provides cash runway to mid 2023 Broker price targets 300p+ (500% upside!) Peer Nasdaq companies valued at $500m+
sev22: Introduction to a full research note on the House Broker's web-site (*free access. DESTINY PHARMA (DEST): CORP Full-year results – looking to partnering deals Destiny’s full year 2021 results contained no surprises given our recent update that accompanied its fundraising in March. The company reported a statutory pre-tax loss of £6.3m (adjusted loss of £5.9m vs. our £6.1m estimate) driven by a 4% decrease in operating costs to £6.3m. Period-end cash of £4.65m (vs. £9.7m at 31 December 2020), together with a £6.5m fundraise in March 2022, provides a runway into mid-2023. With several companies active in the NTCD-M3 data room, we look forward to the company securing a partner to co-fund the Phase 3 trial. Final regulatory discussions (with FDA and EMA) for the Phase 3 trial design are due to be finalised in H1 2022, which should catalyse partnering discussions. We reiterate our rNPV SOTP target price of 306p, which implies an EV of c.£220m, also recognising the upside potential given the substantially higher valuations for companies focused on CDI recurrence (e.g. Seres Therapeutics, which is valued at c.£0.5bn, but arguably with less compelling profiles than NTCD-M3).
sicilian_kan: 45% of open offer shares being taken up (beyond the £6m taken by IIs and HNWIs) is much higher than I was expecting, for the ordinary common shareholder offering. I think it shows great confidence in the company and in the undervaluation of the current share price.
sev22: Morning note from House Broker finnCap Group (full write up at DESTINY PHARMA (DEST): CORP Placing raises £6m with Open Offer up to £1m. Destiny Pharma has raised £6m with up to £1m possible via an Open Offer to progress its two lead assets towards the start of Phase 3 clinical studies and advance commercial partnership discussions. These funds are expected to take the company to key value inflection points (e.g. a partnering deal for the Phase 3 study and commercialisation of NTCD-M3 and progression of XF-73 to a point where we have final clarification from the FDA/EMA as to Phase 3 study design), which is considered a requisite for completing any partnership deal. Both milestones are expected to be reached during 2022. We introduce forecasts for FY 2022, which indicate a net loss of £8.4m. Based on the sum-of-the-parts risk-adjusted NPV and reflecting the share dilution, we reduce our target price to 306p, which leaves substantial upside from the key value inflection points expected in 2022.
gb904150: It could be that the potential partners negotiating position is much stronger if DEST are short on time and funds. Or that the commercials aren't as compelling....but previous presentations suggest they are. The global importance of AMR suggests they are. e..g from DEST slides (Feb 2021 presentation). - cost of complications due to post surgical infections approx $10bn. - XF-73 target market peak US sales opp $1bn Mupirocin effectiveness is waning. Not effective on all strains, encourages AMR build up, is an irritant....etc.... C-difficle: 29,000 USA deaths a year $6bn healthcare burden. $500m NTCD-M3 peak sales opportunity, of which $200m in USA. But DEST have slipped on their timeline it depends on what they are now going to achieve.
gb904150: I'd say this was spectacularly poor timing by the BOD. The dilution could have been much less. The time to raise funds was last year in a strong pharma/biotech environment when with a 150p share price there was excitement around finding partners for phase 3 for XF-73 and NTCD-M3. Instead they held out for as long as possible leading to being low on funds and having to raise in a terrible market. £7m would have been a small fundraise in a position of strength and with minimal dilution at that point. I think DEST has great prospects and a great team but this was really badly handled. Bill Love has a big stake at about 10%. Perhaps the board should hold a bit more too so they keep aligned with shareholders.
sev22: Like every other investor I am finding it very frustrating to see the share price marked down almost daily on very little volume, but once we have a clear and positive way forward with Destiny's other lead product NTCD-M3 this should lead to a substantial re-rating in the stock, regardless of what's going on in Russia. Destiny said only a few weeks ago that they were making good progress in discussions with potential licensing partners for NTCD-M3, with several potential partners active in the data room. This is in line with the company's stated strategy of seeking partners to help co-fund the required Phase 3 trials and lead the commercialisation. Surely news must be due imminently.
gbjbaanb: Nothing will galen until money comes back into the stock market, right now dest could announce they've cited cancer, the common cold, hair loss and weight gain and the share price would barely move. Wait until after Ukraine is a smouldering crater and then the money will start to return.
gb904150: hi 74tom, Thanks for alerting me to that extra info in the latest IMC presentation. I watched the presentation as I was a bit concerned at your suggestion. Neil Clark's explanation during the questions (from 26:30 if you want to skip to it) completely covered it I thought? In short, yes, the patent for NI-CD M3 expires in the next few years but they are not relying on that to give them IP protection. Instead, as it is a biological therapeutic approach they will do a biological licence application (BLA) which will give 12 years commercial protection on approval. In addition, the difficulty to manufacture gives a 2nd level of protection. NC mentions it difficult to find manufactures who can cultivate sufficient quality and consistency of live bacterial spores for the treatment. There's also a very good explanation as to why NT-CD M3 got to where it did. It was developed by Prof. Dale Gerding. He sold his invention to Immupharma. Immupharma spent approx $30m on it getting it through phase 1,2. Immupharma then got bought out by Shire. Shire's focus is solely on orphan drugs so they handed back the tech to Prof. Dale Gerding. He then solicited offers for it and as part of a competitive process DEST won the rights to develop it. As you say, it only cost £2.4m to pick up a treatment that is ready for phase 3 trials. I can imagine Prof Gerding wanted the best price but also the best chance of his life work finally making it to market! It sounds like DEST was a good fit to achieve that. It doesn't sound like there's anything more sinister than that and I trust the DEST team to have done what looks like a good deal. As I say - approx $30m spent on it already and C-diff is as big a problem as it ever was. On your point of funding options, DEST has a cash runway to late 2022 but yes, of course phase 3's will need to be funded. Options there include: equity funding, partners funding, grant funding. Grant funding in particular is a great option because there are specific AMR funds looking to invest to solve what is one of the greatest problems facing medicine. hTTps:// hTTps:// AMR will be a major talking point of the G7 summit taking place in Cornwall this summer. Wouldn't it be convenient if a UK drug/therapeutics company could be championed as part of that? DEST are in a fantastic space at an important time. They've just announced hugely successful Phase 2b trials for XF-73 and yet they now trade at pretty much the same price they were prior to announcing that successful trial! None of that factors in any value for the rest of the XF platform nor any of the sporegen project around COVID. That said - the shorter term share price performance will depend how much funding is raised as equity. To be fair, DEST made a fair offer to existing shareholders to participate last time based on their current holdings. Remember that Bill Love holds a decent % of the shares here - owners and shareholders are aligned, so they tend not to rip off PI's with hugely discounted placings. They also seem to understand the value they are sitting on and don't undersell it.
Destiny Pharma share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Destiny Ph..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220705 22:09:23